Impact of South African 501.V2 Variant on SARS-CoV-2 Spike Infectivity and Neutralization: A Structure-based Computational Assessment
Mary Hongying ChengiD, James KriegeriD, Burak KaynakiD, Moshe ArditiiD, İvet BahariD
Abstract
MotivationThe SARS-CoV-2 variants emerging from South Africa (501.V2) and the UK (B.1.1.7) necessitate rapid assessment of the effects of the corresponding amino acid substitutions in the spike (S) receptor-binding domain (RBD) of the variants on the interactions with the human ACE2 receptor and monoclonal antibodies (mAbs) reported earlier to neutralize the spike. ResultsMolecular modeling and simulations reveal that N501Y, shared by both variants, increases ACE2 binding affinity, and may impact the collective dynamics of the ACE2-RBD complex, occupying a central hinge site that modulates the overall dynamics of the complex. In contrast, the substitutions K417N and E484K in the South African variant 501.V2 would reduce the ACE2-binding affinity by abolishing two interfacial salt bridges that facilitate RBD binding to ACE2, K417(S)-D30(ACE2) and E484 (S)-K31(ACE2). These two mutations may thus be more than compensating the attractive effect induced by N501Y, overall resulting in an ACE2-binding affinity comparable to that of the wildtype RBD. Further analysis of the impact of these mutations on the interactions with mAbs targeting the spike indicate that the substitutions K417N and E484K may also abolish the salt bridges between the spike and selected mAbs, such as REGN10933, BD23, H11_H4, and C105, thus reducing the binding affinity and effectiveness of these mAbs. Contactbahar@pitt.edu Supplementary informationSupplementary data are available at Bioinformatics online.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 58
- Organism
- Assay
- Research Focus
- Approach
Abstract summary
Claude Opus 5.5 · xhigh effort · 18 Oct 2026 · from the abstract · CC BY-NC-ND 4.0
Modeling indicates N501Y strengthens ACE2 binding while K417N and E484K break two interface salt bridges, leaving 501.V2 affinity near wildtype but weakening several monoclonal antibodies.
Spike receptor-binding domain (RBD) substitutions in the variants from South Africa (501.V2) and the UK (B.1.1.7) had to be assessed quickly for their effect on binding of the human ACE2 receptor and of monoclonal antibodies previously reported to neutralize spike. Structure-based modeling is used here to attribute those effects to individual residues and to specific interfacial contacts.
Key results
SuggestedN501Y, carried by both variants, is predicted to raise affinity of the RBD for ACE2, and sits at a central hinge position that the authors say shapes the collective motions of the bound complex.
Derived from molecular modeling and simulations of the ACE2-RBD complex; the abstract quotes no binding constants, free-energy changes or simulation lengths. · Abstract
SuggestedIn 501.V2, K417N and E484K are predicted to lower ACE2 affinity by removing two salt bridges at the interface, and to offset the gain from N501Y so that overall affinity ends up similar to wildtype RBD.
The lost contacts are named as K417(S)-D30(ACE2) and E484(S)-K31(ACE2); the comparison to wildtype affinity is stated qualitatively, with no computed or measured values. · Abstract
SuggestedThe same two substitutions are predicted to break salt bridges with several monoclonal antibodies against spike, reducing their binding and so their effectiveness.
Four antibodies are named (REGN10933, BD23, H11_H4, C105); no neutralization titres, affinity estimates or experimental validation accompany the prediction in the abstract. · Abstract
Methods, data and reproducibility
Structure-based molecular modeling and simulation of the SARS-CoV-2 spike receptor-binding domain bound to human ACE2 and to neutralizing monoclonal antibodies, comparing wildtype with the substitutions found in the 501.V2 and B.1.1.7 variants, with attention to interfacial salt bridges and to the collective dynamics of the complex.
- models of the spike RBD in complex with the receptor, wildtype versus variant substitutions · SARS-CoV-2 spike with human ACE2
- complexes of spike with monoclonal antibodies previously reported to neutralize it · SARS-CoV-2
- Methods & tools
- molecular modeling and simulations, REGN10933, BD23, H11_H4, C105
- Reproducibility gaps
- Supplementary data are said to be available with the journal version, but no structure accessions, simulation protocol or code location appear in the abstract.
Limitations (2)
- Everything rests on modeling and simulation: no binding measurements, neutralization assays or computed affinity values are reported, and the hedged wording (may, would) signals predictions rather than results. · noted in this summary
- The analysis is limited to the named RBD substitutions and the interface contacts they make; it covers four selected monoclonal antibodies rather than a polyclonal response, and nothing outside the receptor-binding domain is assessed. · noted in this summary
Who should read:Read this if you follow SARS-CoV-2 variant effects on receptor binding or antibody escape and want a residue-level structural rationale for N501Y, K417N and E484K.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- In silico investigation of the new UK (B.1.1.7) and South African (501Y.V2) SARS-CoV-2 variants with a focus at the ACE2-Spike RBD interface
Bruno O. Villoutreix, Vincent Cálvez, … Abdel‐Majid Khatib·International Journal of Molecular SciencesPeer-reviewed·Feb 8, 2021
- Molecular dynamic simulation reveals E484K mutation enhances spike RBD-ACE2 affinity and the combination of E484K, K417N and N501Y mutations (501Y.V2 variant) induces conformational change greater than N501Y mutant alone, potentially resulting in an escape mutant
G. Nelson, O. Buzko, … P. R. Soon-Shiong·bioRxiv·Jan 13, 2021
- Allosteric Cross-Talk Among SARS-CoV-2 Spike's Receptor-Binding Domain Mutations Triggers an Effective Hijacking of Human Cell Receptor
A. Spinello, A. Saltalamacchia, … A. Magistrato·bioRxiv·Apr 30, 2021
- SARS-CoV-2 variants resist antibody neutralization and broaden host ACE2 usage
- Effects of common mutations in the SARS-CoV-2 Spike RBD domain and its ligand the human ACE2 receptor on binding affinity and kinetics
M. I. Barton, S. MacGowan, … P. A. van der Merwe·bioRxiv·May 18, 2021
- Experimental evidence for enhanced receptor binding by rapidly spreading SARS-CoV-2 variants
C. Laffeber, K. de Koning, … J. Lebbink·bioRxiv·Feb 22, 2021